sofosbuvir CAS NO.1190307-88-0

1,we produce and sell good chemicals around the world.

2,our success rate is about 95%. this means, if customer order is accepted, the probability that the customer will obtain the ordered substances, is 95%.

3,our staff consists of highly qualified individuals with bsc, msc and ph.d degrees in chemistry, as well as excellent carbohydrates,nucleosides, small molecules and rare chemicals.

4,imaginechem's chemists are skilled at performing complex, multi-step syntheses and solving difficult chemistry-related problems. because of our better, concentracted size and low overheads, we are able to offer prompt quotations, very competitive prices, high quality products and fast delivery.

5,all chemicals are typically >97% for building blocks, the structure and purity is confirmed by nmr and lc-ms. intermediates and final products are analyzed by gc, hplc, ir, nmr, ms, elemental analysis, atom-absorpting analysis and crystallographical methods.

62,customers-oriented strategy, exclusive supply chain management, professional r&d team, experienced production workers, energetic sales team enable us to offer best service andgood-value products to all of our customers and gradually reach our final goals: becoming global leading supplier for portable products and solutions.

Sofibuvir is a prodrug that metabolizes into the active antiviral 2' -deoxy-2 '-alpha-fluoro-β-c-methyluridine 5' -monophosphate and is currently in phase 3 clinical trials for the treatment of hepatitis C. Studies have shown that Sofibuvir is a nucleotide inhibitor of hepatitis C virus and has a selective inhibitory effect on HCVNS5B polymerase. Sofibuvir, also known as Sofibuvir or Sofloubuvir, is the world's first oral treatment for hepatitis C. It is one of the most important new drugs approved in the United States in 2013. When used for the treatment of specific genotypes of chronic hepatitis C, it can eliminate the need for the traditional injectable drug interferon (IFN). Developed by Gilead Sciences, the world's largest maker of anti-HIV drugs, the drug is known as Sofosbuvir and Sovaldi, with peak global sales likely to exceed $10 billion. On December 6, 2013, the US Food and Drug Administration (FDA) approved Sofibuvir (Sovaldi) for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi is the first safe, effective drug to treat certain types of HCV infection without the use of interferon. Hepatitis C is a viral disease that can cause inflammation of the liver, leading to weakened liver function or liver failure. Most patients with HCV infection do not develop Chemicalbook symptoms until liver damage becomes more apparent, a process that can take several years. Some chronic HCV infections develop scarring and cirrhosis over many years, which can lead to complications such as bleeding, jaundice (yellowing of the eyes or skin), ascites, infection, or liver cancer. About 3.2 million Americans are infected with hepatitis C virus, according to the Centers for Disease Control and Prevention. Sofibvir is a nucleotide analogue inhibitor that blocks a specific protein that hepatitis C virus needs to replicate. Sofibuvir is used as an antiviral combination therapy for chronic HCV infection. There are several different types of HCV infection. Depending on the type of HCV infection a patient has, treatment options may include sofibuvir and ribavirin, or sofibuvir, ribavirin and peginterferon alpha. Ribavirin and pegylated interferon alpha are also two drugs used to treat HCV infection. Sofibuvir is the third drug to be approved under FDA breakthrough therapy status. If preliminary clinical evidence shows that a drug provides a substantial improvement over existing treatments for patients with serious or life-threatening diseases, sponsors can apply for breakthrough therapy status with the FDA. Us patents valid: March 26, 2029 (US patents 7964580 and 8334270), April 3,2025 (US patents 7429572 and 8415322).